<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Older Women Face Estrogen Profiteering</title>
    <meta content="2" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="1991" name="publication_year"/>
    <meta content="Wednesday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="22" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="477800"/>
      <doc.copyright holder="The New York Times" year="1991"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">ESTROGEN</classifier>
        <classifier class="indexing_service" type="descriptor">PRICES</classifier>
        <classifier class="indexing_service" type="descriptor">DRUGS (PHARMACEUTICALS)</classifier>
        <classifier class="indexing_service" type="descriptor">WOMEN</classifier>
        <classifier class="indexing_service" type="descriptor">GENERIC AND BRAND NAME PRODUCTS</classifier>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="general_descriptor">Estrogen</classifier>
        <classifier class="online_producer" type="general_descriptor">Prices (Fares, Fees and Rates)</classifier>
        <classifier class="online_producer" type="general_descriptor">Generic and Brand Name Products</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Women</classifier>
        <classifier class="online_producer" type="general_descriptor">Hormones</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="19911002T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9D0CE7DD113AF931A35753C1A967958260" item-length="196" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Older Women Face Estrogen Profiteering</hl1>
      </hedline>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>The day "A New Lease for Estrogen" (editorial, Sept. 16) extolled the good news about estrogen replacement therapy for post-menopausal women, I received notice from my American Association for Retired Persons pharmacy that I will no longer be able to buy estrogen in generic form: "the sole manufacturer of generic conjugated estrogens is no longer producing this product." I have been on estrogen 10 years for osteoporosis. Now I will have to buy the much more expensive Premarin, the trade name for conjugated estrogen tablets made by Wyeth-Ayerst.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>The day "A New Lease for Estrogen" (editorial, Sept. 16) extolled the good news about estrogen replacement therapy for post-menopausal women, I received notice from my American Association for Retired Persons pharmacy that I will no longer be able to buy estrogen in generic form: "the sole manufacturer of generic conjugated estrogens is no longer producing this product." I have been on estrogen 10 years for osteoporosis. Now I will have to buy the much more expensive Premarin, the trade name for conjugated estrogen tablets made by Wyeth-Ayerst.</p>
        <p>As a long-term beneficiary of estrogen, I applaud the research validating its use for more women. However, it appears that part of the pharmaceutical industry has taken steps toward making a financial killing from a vastly increased market. I am appalled that older women, many on limited fixed incomes, are not to have estrogen in its generic form at reasonable prices, but will be forced to buy Premarin at much higher prices.</p>
        <p>The Congressional committee concerned with the pricing of medications in the United States should look into this. MILDRED P. KATZ Cambridge, N.Y., Sept. 17, 1991</p>
      </block>
    </body.content>
  </body>
</nitf>
